Novo Nordisk's oral Wegovy generated DKK 3.22 billion $496 million in Q2 2026 revenue, far ahead of Eli Lilly's newly approved Foundayo at $98 million, but GlobalData's Sara Reci forecasts Lilly will overtake by 2028 on retatrutide strength and widen the gap through 2032. The early efficacy edge…
Novo Nordisk's oral Wegovy generated DKK 3.22 billion, equal to $496 million, in revenue during the second quarter of 2026. That is roughly five times the $98 million that Eli Lilly's Foundayo produced in the same period, making this the first review of commercial sales data since Foundayo's April 2026 approval by the U.S. Food and Drug Administration. Tristan Manalac, senior staff writer at BioSpace, conducted the review, examining the quarterly sales figures and the analyst forecasts built on them.
Q2 2026 was Foundayo's first full commercial quarter, and analysts had approximately three months of sales data on the oral obesity market as of August 19, 2026. The early reading favors Novo. Sara Reci, managing pharma analyst at GlobalData, put it directly: "The oral market, at least in its early phase, favors Novo Nordisk."
One quarter is not a trend, and the injectable history is a reminder that early leads have inverted before. What matters now is whether Foundayo's launch curve steepens in the quarters ahead. The forecast horizon differs sharply from the current sales picture. Reci projects that Lilly will overtake Novo in 2028 and progressively widen its lead through 2032, largely on the strength of retatrutide , Lilly's triple GLP-1/GIP/glucagon receptor agonist. Lilly plans an FDA submission for retatrutide in 2027.
Efficacy in the early going also favors Novo. At 72 weeks, oral Wegovy produced 16.6% weight loss versus 11.2% for Foundayo, though no head-to-head trial has directly compared the two drugs.
Analysts attribute Novo's early oral lead to several factors beyond first-mover timing: Wegovy brand recognition, prescriber familiarity with semaglutide , years of clinical experience with the molecule, and the efficacy edge visible in the 72-week data. The brand argument is direct: Wegovy is the established name in injectable obesity care, and oral Wegovy inherits that recognition. The familiarity argument is structural. Semaglutide has been in front of primary care physicians and endocrinologists for most of the past decade through Ozempic and Wegovy, and a molecule a prescriber has used before is easier to prescribe in a new form than one that is entirely new. Sadaf Javed, manager of forecasting at DelveInsight, framed the durability question. "Ultimately, Novo’s leadership will depend less on being first and more on continuously strengthening the franchise across efficacy, convenience, access, and value."
Foundayo brings structural advantages of its own. It is a small molecule, which gives it simpler administration and a different manufacturing cost curve than a peptide. Those economics could help Lilly compete on price and convenience, especially outside the United States. Srikripa Devarakonda, vice president of biotechnology equity research at Truist Securities, said: "Our view is that Foundayo is a bigger ex-U.S. play."
Convenience is not a minor variable in chronic metabolic disease. After taking oral Wegovy, patients must wait 30 minutes before any additional food or drink intake, a constraint tied to the peptide's method of oral absorption. Foundayo's small-molecule formulation does not carry the same requirement. For a therapy taken for years, that difference can compound into measurable adherence gaps.
The early market thus presents a clean contest: a delivery-constrained peptide with a deep track record against an unconstrained small molecule with a powerful commercial machine behind it. The 72-week efficacy gap says the peptide still has the stronger pharmacology in trials. Whether that pharmacology survives real-world adherence and price competition is the question the next several quarters will answer.
The 16.6% and 11.2% figures come from separate sponsor-led trials, not from a controlled head-to-head comparison. The doses behind the results, sample sizes, statistical significance levels, and confidence intervals were not disclosed. Cross-trial comparisons of weight-loss drugs are provisional because differences in trial populations, run-in diets, lifestyle coaching, and titration schedules can shift outcomes by more than the 5.4 percentage point gap seen here. Means also obscure the distribution of responses: in obesity trials, the proportion of patients reaching clinically meaningful thresholds is often a more useful guide to real-world value than the average, and that proportion was not reported.
The comparison does establish direction. At the same 72-week time point, oral Wegovy produced larger mean weight loss than Foundayo in their respective trials. It does not establish superiority, because no single trial assigned patients to both drugs. That missing direct comparison is the central evidence gap in the oral obesity market. A head-to-head trial with matched populations, an identical lifestyle program, and pre-specified margins would resolve it; whether either company is planning such a trial has not been disclosed.
Durations also vary across programs. The May 2026 retatrutide Phase 3 study measured outcomes over 80 weeks, eight weeks beyond the 72-week benchmark used in the oral comparison. Indirect comparisons across different time points add another layer of uncertainty, and single time-point means say nothing about durability beyond that point, the proportion of patients who regained weight, or tolerability. Those variables will be filled in by real-world evidence, not by the registration programs.
The 30-minute restriction attached to oral Wegovy is not a dosing quirk. It is a window into the difficulty of delivering a peptide by mouth. Semaglutide is a 31-amino-acid peptide, far larger than a typical small-molecule drug, and the gastrointestinal tract is built to keep such molecules out. Gastric acid denatures proteins, digestive enzymes cleave peptide bonds, and the intestinal epithelium admits small lipophilic compounds far more readily than large hydrophilic peptides. Oral semaglutide's formulation therefore depends on an absorption enhancer that transiently increases passage across the gut wall. Food and drink alter gastric pH, gastric emptying, and the luminal environment on which that enhancer depends, which is why dosing must be separated from any other intake by 30 minutes.
Manufacturing economics sharpen the contrast. Semaglutide is produced by peptide synthesis, a multi-step process of chain assembly, side-chain modification, and purification that carries a higher cost of goods than conventional organic synthesis of a small molecule. Foundayo's small-molecule structure scales through standard manufacturing routes at lower marginal cost per dose. In a chronic therapy taken daily, unit cost differences compound into large budget effects for payers and health systems, and they set the floor for what a peptide product must justify in outcomes.
Foundayo also imposes no waiting interval tied to absorption. For patients, the peptide's meal-timing requirement is a daily, indefinite burden, the kind of real-world friction that shows up in persistence analyses rather than in trial means. That practical difference is one reason Devarakonda reads Foundayo as the bigger international play: in ex-U.S. markets where patients pay more out of pocket, a simpler and cheaper small molecule can win regardless of the efficacy gap.
The biology cuts both ways, though. Even with the delivery penalty, oral Wegovy produced the larger weight loss at 72 weeks, and CagriSema, retatrutide, and zenagamtide have all shown that peptide-based pharmacology still holds the efficacy lead in this class. The oral contest is therefore a live test of how much of that lead survives contact with convenience and price. For peptide scientists, the question is not whether peptides work, but whether a 31-amino-acid molecule with a meal-timing rule can hold a market against a small molecule that asks nothing of the patient.
The FDA approved Foundayo in April 2026, opening the U.S. oral obesity market. Novo Nordisk filed for approval of CagriSema , its combination of semaglutide and the amylin analogue cagrilintide , in December 2025. The FDA's decision date for CagriSema has not been disclosed.
CagriSema's path to that filing was bruising. In December 2024, Phase 3 data showed the combination produced greater weight loss than semaglutide or cagrilintide alone, but the result fell below the efficacy bar Novo itself had set, erasing approximately $72 billion in market capitalization in the reaction window that followed. The market's response measured how high expectations had climbed: a combination that beat both of its components was treated as a disappointment because the headline number came in below the company's own guidance.
In February 2026, CagriSema failed to show statistical non-inferiority to Lilly's Zepbound in a Phase 3 head-to-head trial. Non-inferiority trials are built around a pre-specified margin: the experimental drug must land within that margin of the active comparator to support a claim that it is not unacceptably worse. Failing the test means the data do not support an equivalence claim, even though they also do not prove inferiority. The practical consequence is positioning. CagriSema cannot be presented as equivalent to the leading injectable, and the December 2025 filing remains under review with no disclosed decision date.
History frames the current forecast. Novo secured approval for Ozempic in late 2017. Lilly entered the GLP-1 arena in 2022 with Mounjaro , a gap of roughly five years. Within three years of Mounjaro's launch, Lilly had overtaken Novo as the market frontrunner. That sequence is the backdrop for Reci's expectation that the same commercial machine overtakes Novo in the oral segment by 2028. It is also a reminder that the earlier lead was overturned faster than it was built, which is why the Q2 2026 revenue gap is not being read as a durable verdict.
Retatrutide is the reason analysts expect Lilly's lead to widen. It is a triple agonist, engaging the GLP-1, GIP, and glucagon receptors in a single molecule. The GLP-1 and GIP components drive glucose-dependent insulin secretion and central appetite regulation; the glucagon component raises energy expenditure, the element that separates the design from dual-agonist predecessors. In May 2026, a Phase 3 study showed 26.1% placebo-adjusted weight loss at the highest dose over 80 weeks. In June 2026, a separate late-stage readout in patients with obesity or overweight and type 2 diabetes showed a 20.8% weight reduction at the highest dose versus 4% for placebo. Neither result came from a direct comparison with competing therapies, and the two numbers are not directly comparable with each other: the May figure is placebo-adjusted at a documented 80 weeks, while the duration of the June type 2 diabetes trial was not reported.
Timing links the data to the forecast. A planned 2027 FDA submission points to a commercial launch in the same period Reci has Lilly overtaking Novo. The 2028 projection, in effect, assumes retatrutide's registration program stays on schedule and that the Phase 3 results hold across the full dataset.
Novo's pipeline response is zenagamtide , formerly amycretin, a single molecule that combines GLP-1 and amylin activity. The design differs from CagriSema, which delivers semaglutide and cagrilintide as two separate peptides in a fixed ratio. A unimolecular agonist carries both activities with a single pharmacokinetic profile and a single manufacturing process. The amylin biology is complementary to GLP-1: amylin slows gastric emptying, suppresses postprandial glucagon,…
Peptides referenced: Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Amylin, Glucagon, Amycretin, GLP-1.
Related reading: Copper Peptides Go Mainstream in Skin Care as GHK-Cu Leads the Field, Dentist's TV Warning Adds Oral Health to GLP-1 Risk Discussion, Weekly GLP-1 Drug Beats Daily Insulin in Thalassaemia-Linked Diabetes, IndexBox Lists US$4,000 UK Peptide Serum Report, No Findings.